Technology including intellectual property and knowhow, developed by the UK Gene Therapy Consortium, made up of researchers at Imperial College London, the University of Oxford and Edinburgh University has been licensed to Boehringer Ingelheim in a continuation of a licence agreement first announced in 2018.
Accelerated development of a potential treatment for cystic fibrosis
Sectors: Medical research, Pharmaceuticals
A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier. Find out more
Proposed use Research into Charcot-Marie Tooth Disease (Type 1A). Research into autoimmune neurological disorders would be the main ... Find out more
Novel genetic engineering tools that can be applied to Mycoplasma expanding its utility as a synthetic biology asset. Find out more
The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim. Find out more
Sign up for updates
Sign up for monthly technology alerts via email, and find other ways to connect with us.